Related references
Note: Only part of the references are listed.Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Danling Gu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato et al.
LANCET (2021)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
Hong Zhou et al.
ONCOTARGETS AND THERAPY (2020)
Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors
Wataru Kawahata et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
James J. y Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors
Barbara Brandhuber et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis
Wataru Kawahata et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry
James A. Bull et al.
CHEMICAL REVIEWS (2016)
Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis
Yan Lou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
Matthew S. Davids et al.
FUTURE ONCOLOGY (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL
Louis M. Staudt et al.
BLOOD (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
Aqueous-phase Suzuki-Miyaura cross-coupling reactions of free halopurine bases
Petr Capek et al.
SYNTHESIS-STUTTGART (2006)
Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase
WN Khan
IMMUNOLOGIC RESEARCH (2001)
Functional dissection of BCR signaling pathways
T Kurosaki
CURRENT OPINION IN IMMUNOLOGY (2000)
Share Paper
